摘要
目的分析阿戈美拉汀联合普拉克索治疗特发性快速眼球动睡眠期行为障碍(iRBD)合并焦虑、抑郁患者的临床有效性,为临床上iRBD合并焦虑、抑郁的治疗提供参考。方法收集武汉市第一医院睡眠医学中心2018年9月—2021年12月收治iRBD合并焦虑、抑郁患者60例,完善颅脑磁共振等影像学检查,采用多导睡眠监测仪(PSG)记录患者夜间12 h的睡眠状况。采用随机对照原则,将患者分为对照组和治疗组,每组30例。对照组给予普拉克索片0.125 mg,每晚1次,治疗组在对照组基础上,给予阿戈美拉汀25 mg,服用3个月。治疗前及治疗3个月后采用匹兹堡睡眠质量指数量表(PSQI)、爱泼沃斯嗜睡量表(ESS)、汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、焦虑自评量表(SAS)、抑郁自评量表(SDS)、快动眼睡眠行为障碍筛查量表(RBDSQ)评价两组患者睡眠、心理状态、RBD梦境及行为异常状况。结果治疗前两组患者性别、年龄、病程、PSG参数、PSQI、ESS、HAMD、HAMA、SAS、SDS、RBDSQ均差异无统计学意义(P>0.05);治疗3个月后,治疗组患者PSQI、ESS、HAMD、HAMA、SAS、SDS、RBDSQ分值下降明显,与对照组比较差异有统计学意义(P<0.05)。结论阿戈美拉汀联合普拉克索治疗不仅可改善iRBD合并焦虑、抑郁患者的睡眠质量、焦虑抑郁状态,还更好改善快速眼球动睡眠期的行为障碍。
Objective To summarize and analyze the clinical efficacy of agomelatine combined with pramipexole in treating iRBD patients with anxiety and depression,to provide a reference for the clinical treatment of iRBD patients with anxiety and depression.Methods A total of 60 cases of iRBD complicated with anxiety and depression patients admitted to the Sleep Medical Center of the First Hospital of Wuhan from September 2018 to December 2021 were collected,and the brain MRI and other imaging examinations were completed.The sleep state of patients at night for 12 hours was recorded by polysomnography(PSG).Using the principle of randomized control,the patients were randomly divided into control group and experimental group,30 cases in each group.The control group was given pramipexole tablets 0.125 mg once a night,and the treatment group was given 25 mg of agomelatine on the basis of the control group for 3 months.Before treatment and 3 months after treatment,Pittsburgh sleep quality index(PSQI),Epworth Sleepiness Scale(ESS),Hamilton Depression Scale(HAMD),Hamilton Anxiety Scale(HAMA)Anxiety Self-Evaluation Scale(SAS),Depression Self-Evaluation Scale(SDS)and Rapid-eye-movement Sleep Behavior Disorder Screening Questionnaire(RBDSQ)were used to evaluate the sleep,mental state,dream and abnormal of RBD of the two groups.Results Before treatment,there was no difference in gender,age,course of disease,and PSG parameters between the two groups;There was no significant difference in PSQI,ESS,HAMD,HAMA,SAS,SDS,and RBDSQ(P>0.05);After three months of treatment,the scores of PSQI,ESS,HAMD,HAMA,SAS,SDS and RBDSQ in the experimental group decreased significantly compared with those in the control group(P<0.05).Conclusion Agomelatine combined with pramipexole treatment can not only improve sleep quality,anxiety,and depression status of iRBD patients,but also better improve the behavioral disorders during rapid eye movement sleep.
作者
尤红
梅俊华
徐金梅
陈国华
刘敏珍
龚雪
杨青
YOU Hong;MEI Junhua;XU Jinmei;CHEN Guohua;LIU Minzhen;GONG Xue;YANG Qing(Sleep Medicine Center of Department of Neurology,the First Hospital of Wuhan City,Wuhan 430022,China)
出处
《医药导报》
CAS
北大核心
2023年第2期198-202,共5页
Herald of Medicine
基金
武汉市卫健委项目(WX20B23)。
